Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

BACKGROUND: Traditional adherence measures such as proportion of days covered (PDC)
and medication possession ratio (MPR) are limited in their ability to explain patient …

Background Hydroxychloroquine (HCQ) is the standard of care medication for most SLE
patients, however nonadherence is common. We investigated longitudinal patterns and …

Background TV-46000 is a long-acting, subcutaneous, antipsychotic agent that combines
risperidone and an innovative, copolymer-based drug delivery technology in a suspension …

Background Schizophrenia is a chronic mental disorder associated with substantial
morbidity and mortality affecting 0.25–1.6% of adults in the USA. Antipsychotic treatment is …

Background To date, there have been no studies evaluating adherence to clozapine with
electronic adherence monitoring (EAM) such as the Medication Event Monitoring System …

Objective This study aims to describe the utilization patterns of antipsychotic (AP) medication
in patients with schizophrenia (SCZ), three years after initiating or reinitiating a given AP …

This retrospective study evaluated the benefit of following different long-acting injectable
(LAI) initiation strategies based on the timing of behavioral and clinical events among …

Background: Much of the burden associated with schizophrenia is attributed to its early
onset and chronic nature. Treatment with once monthly paliperidone palmitate (PP1M) is …